Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy

NCT04968834 · View on ClinicalTrials.gov ↗

Study Summary

This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.

Interventions

  • GENETIC Genomic profiling

Study Locations (8)

Massachusetts

  • Boston Children's Hospital — Boston
  • Dana Farber Cancer Institute — Boston

Connecticut

  • Connecticut Children's Medical Center — Hartford

Maine

  • Maine Medical Center — Portland

New Hampshire

  • Dartmouth-Hitchcock — Lebanon

New York

  • Albany Medical Center — Albany

Rhode Island

  • Lifespan Cancer Institute — Providence

Vermont

  • University of Vermont Medical Center — Burlington

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-06-11
Est. Completion 2033-06

Sponsor

Dana-Farber Cancer Institute

819 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04968834

The ClinicalTrials.gov registry entry for NCT04968834 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 819 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention — of which Genomic profiling is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04968834 reports 8 study locations spanning 7 distinct geographic areas — top geographies include Massachusetts, Connecticut, Maine. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04968834 about?

NCT04968834 is a clinical study titled "Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy". This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and ...

What is the current status of trial NCT04968834?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-06-11. Estimated completion is 2033-06.

What conditions does trial NCT04968834 study?

This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04968834?

The interventions under investigation include: Genomic profiling (GENETIC). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04968834?

This trial is sponsored by Dana-Farber Cancer Institute, which has 819 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04968834 being conducted?

This trial has 8 study locations across Connecticut, Maine, Massachusetts, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial